Journal: OncoImmunology

Article Title: PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor

doi: 10.1080/2162402x.2018.1541535

Figure Lengend Snippet: Figure 1. Comparison of PD-L2 expression level in CGGA and TCGA cohorts with different WHO grades (a, c) and IDH status (b, d). PD-L2 was significantly increased in GRADE IV and IDH-wildtype gliomas in CGGA and TCGA data set. Photographs of immunohistochemical staining of PD-L2 in different grades of gliomas. Positive cells are stained brown. (e) Diffuse astrocytoma (WHO grade II). (f) Anaplastic astrocytoma (WHO grade III). (g) Glioblastoma multiforme (WHO grade IV). Magnification, x200. *, **, ***, and **** indicate p < 0.05, p < 0.01, p < 0.001 and p < 0.0001, respectively.

Article Snippet: Anti-PD-L2 antibody (18251–1-AP, dilution:1:200, Proteintech) was used to detect PD-L2 protein expression.

Techniques: Comparison, Expressing, Immunohistochemical staining, Staining

Journal: OncoImmunology

Article Title: PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor

doi: 10.1080/2162402x.2018.1541535

Figure Lengend Snippet: Figure 2. Comparison of PD-L2 expression level in CGGA and TCGA cohorts with different TCGA molecular subtypes (a, c), PD-L2 was significantly increased in mesenchymal subtype (p < 0.0001). ROC curves exhibited highly sensitivity in predicting mesenchymal subtype (b, d). Receiver operating characteristic (ROC) curve for mesenchymal subtype prediction in CGGA and TCGA datasets. ROC curve analysis showed that PD-L2 had highly sensitivity and specificity to predict mesenchymal subtype in CGGA and TCGA database. Area under curve(AUC) was 0.903 and 0.816, respectively.

Article Snippet: Anti-PD-L2 antibody (18251–1-AP, dilution:1:200, Proteintech) was used to detect PD-L2 protein expression.

Techniques: Comparison, Expressing

Journal: OncoImmunology

Article Title: PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor

doi: 10.1080/2162402x.2018.1541535

Figure Lengend Snippet: Figure 4. PD-L2 related inflammation activities in CGGA and TCGA cohorts. In pie charts, positive correlations are displayed in green and negative correlations in red. Color intensity and the size of the circle are proportional to the correlation coefficients.

Article Snippet: Anti-PD-L2 antibody (18251–1-AP, dilution:1:200, Proteintech) was used to detect PD-L2 protein expression.

Techniques:

Journal: OncoImmunology

Article Title: PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor

doi: 10.1080/2162402x.2018.1541535

Figure Lengend Snippet: Figure 3. The biology function of PD-L2 positively related genes in CGGA and TCGA cohorts. The biological functions related with immune response, T cell proliferation, defense response to virus, cytokine secretion, NF-kappaB signaling and cellular response to mechanical stimulus were significantly positively correlated with PD-L2 expression (p < 0.05).

Article Snippet: Anti-PD-L2 antibody (18251–1-AP, dilution:1:200, Proteintech) was used to detect PD-L2 protein expression.

Techniques: Virus, Expressing

Journal: OncoImmunology

Article Title: PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor

doi: 10.1080/2162402x.2018.1541535

Figure Lengend Snippet: Figure 6. Forest plot of hazard ratios for overall survival assessed by PD-L2 expression and clinicopathological factors. PD-L2 expression was an independent prognostic factor after adjusting age, grade, IDH status and 1p19q status in TCGA and CGGA datasets.

Article Snippet: Anti-PD-L2 antibody (18251–1-AP, dilution:1:200, Proteintech) was used to detect PD-L2 protein expression.

Techniques: Expressing

Journal: OncoImmunology

Article Title: PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor

doi: 10.1080/2162402x.2018.1541535

Figure Lengend Snippet: Figure 5. The PD-L2 survival curves of glioma, LGG and GBM in CGGA and TCGA cohorts. Kaplan–Meier survival analysis showed that high expression of PD-L2 conferred a significantly worse prognosis in glioma, LGG and GBM patients, respectively.

Article Snippet: Anti-PD-L2 antibody (18251–1-AP, dilution:1:200, Proteintech) was used to detect PD-L2 protein expression.

Techniques: Expressing

Journal: Genes & Diseases

Article Title: PDCD2 as a prognostic biomarker in glioma correlates with malignant phenotype

doi: 10.1016/j.gendis.2023.101106

Figure Lengend Snippet: PDCD2 expression in pan-cancer. (A) Examining the TIMER database uncovers PDCD2 expression in pan-cancers. (B) Pan-cancer analysis of PDCD2 expression in TCGA/GTEx. (C) Data from the UALCAN database on PDCD2 protein in pan-cancer analysis. ns, P > 0.05; ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001.

Article Snippet: The technique of immunohistochemistry (IHC) was carried out following the methods described earlier., The xenograft sections of nude mice were treated with primary antibodies against PDCD2 (Proteintech, 10725-1-AP) and Ki67 (sc-23900, Santa Cruz) for overnight incubation at 4 °C.

Techniques: Expressing

Journal: Genes & Diseases

Article Title: PDCD2 as a prognostic biomarker in glioma correlates with malignant phenotype

doi: 10.1016/j.gendis.2023.101106

Figure Lengend Snippet: The PDCD2 prognostic values in pan-cancer. (A) The impact of PDCD2 expression on the overall survival rate of patients with ACC, GBMLGG, LIHC, KIRC, or SARC. (B) The disease-specific survival for PDCD2 in ACC, GBMLGG, and UCEC. (C) The progress-free survival for PDCD2 in ACC, GBMLGG, HNSC, LIHC, OV, and UCEC.

Article Snippet: The technique of immunohistochemistry (IHC) was carried out following the methods described earlier., The xenograft sections of nude mice were treated with primary antibodies against PDCD2 (Proteintech, 10725-1-AP) and Ki67 (sc-23900, Santa Cruz) for overnight incubation at 4 °C.

Techniques: Expressing

Journal: Genes & Diseases

Article Title: PDCD2 as a prognostic biomarker in glioma correlates with malignant phenotype

doi: 10.1016/j.gendis.2023.101106

Figure Lengend Snippet: ROC curve analysis of PDCD2 in pan-cancer. ROC curve analysis of PDCD2 in CHOL, COAD, LIHC, STAD, PAAD, and READ (A) , ESAD, ESCA, and LUSC (B) , GBMLGG, GBM, and LGG (C) , KICH, TGCT, and UCS (D) . TPR, true positive rate; FPR, false positive rate.

Article Snippet: The technique of immunohistochemistry (IHC) was carried out following the methods described earlier., The xenograft sections of nude mice were treated with primary antibodies against PDCD2 (Proteintech, 10725-1-AP) and Ki67 (sc-23900, Santa Cruz) for overnight incubation at 4 °C.

Techniques:

Journal: Genes & Diseases

Article Title: PDCD2 as a prognostic biomarker in glioma correlates with malignant phenotype

doi: 10.1016/j.gendis.2023.101106

Figure Lengend Snippet: Mutational analysis of PDCD2. (A) Hot spots of mutation of PDCD2. (B) A summary of PDCD2 mutation types and their distribution among different cancers. (C) Correlation of PDCD2 CNV with mRNA expression in pan-cancer. ns, P > 0.05; ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001.

Article Snippet: The technique of immunohistochemistry (IHC) was carried out following the methods described earlier., The xenograft sections of nude mice were treated with primary antibodies against PDCD2 (Proteintech, 10725-1-AP) and Ki67 (sc-23900, Santa Cruz) for overnight incubation at 4 °C.

Techniques: Mutagenesis, Expressing

Journal: Genes & Diseases

Article Title: PDCD2 as a prognostic biomarker in glioma correlates with malignant phenotype

doi: 10.1016/j.gendis.2023.101106

Figure Lengend Snippet: PDCD2 is correlated with clinical characteristics in GBMLGG. The PDCD2 was up-regulated in GBMLGG (A) , and associated with WHO grade, IDH status, primary therapy outcome, age, race, histological type, OS event, DSS event, and PFI event (B – J) (data from TCGA). PDCD2 is correlated with clinical characteristics in glioma, including the WHO grade, IDH mutation status, 1p/19q co-deletion status, IDH mutation status & 1p/19q co-deletion status, gender, and histology (K–P) (data from CGGA). G2, grade II; G3, grade III; G4, grade IV; PR, partial response; CR, complete response; PD, progressive disease; OS, overall survival; DSS, disease-specific survival; PFS, progression-free survival; WT, wild type; Mut, mutant. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001.

Article Snippet: The technique of immunohistochemistry (IHC) was carried out following the methods described earlier., The xenograft sections of nude mice were treated with primary antibodies against PDCD2 (Proteintech, 10725-1-AP) and Ki67 (sc-23900, Santa Cruz) for overnight incubation at 4 °C.

Techniques: Mutagenesis

Journal: Genes & Diseases

Article Title: PDCD2 as a prognostic biomarker in glioma correlates with malignant phenotype

doi: 10.1016/j.gendis.2023.101106

Figure Lengend Snippet: PDCD2 is correlated with prognosis in GBMLGG. The correlation between PDCD2 and OS in 1p/19q co-deletion status (A) , gender (both female and male) (B, C) , race (white) (D) , age (E, F) , and histological type (G) of GBMLGG.

Article Snippet: The technique of immunohistochemistry (IHC) was carried out following the methods described earlier., The xenograft sections of nude mice were treated with primary antibodies against PDCD2 (Proteintech, 10725-1-AP) and Ki67 (sc-23900, Santa Cruz) for overnight incubation at 4 °C.

Techniques:

Journal: Genes & Diseases

Article Title: PDCD2 as a prognostic biomarker in glioma correlates with malignant phenotype

doi: 10.1016/j.gendis.2023.101106

Figure Lengend Snippet: Univariate and multivariate Cox regression analyses of clinical characteristics associated with OS of glioma.

Article Snippet: The technique of immunohistochemistry (IHC) was carried out following the methods described earlier., The xenograft sections of nude mice were treated with primary antibodies against PDCD2 (Proteintech, 10725-1-AP) and Ki67 (sc-23900, Santa Cruz) for overnight incubation at 4 °C.

Techniques:

Journal: Genes & Diseases

Article Title: PDCD2 as a prognostic biomarker in glioma correlates with malignant phenotype

doi: 10.1016/j.gendis.2023.101106

Figure Lengend Snippet: The ability of PDCD2 to predict the GBMLGG patients' prognosis. Construction and evaluation of nomogram used for predicting OS (A) , DFS (B) , and PFS (C) of GBMLGG patients. The calibration curve and Hosmer–Lemeshow test of nomograms in the TCGA-GBMLGG cohort for OS (D) , DFS (E) , and PFS (F) .

Article Snippet: The technique of immunohistochemistry (IHC) was carried out following the methods described earlier., The xenograft sections of nude mice were treated with primary antibodies against PDCD2 (Proteintech, 10725-1-AP) and Ki67 (sc-23900, Santa Cruz) for overnight incubation at 4 °C.

Techniques:

Journal: Genes & Diseases

Article Title: PDCD2 as a prognostic biomarker in glioma correlates with malignant phenotype

doi: 10.1016/j.gendis.2023.101106

Figure Lengend Snippet: Interaction network of PDCD2. The network of PDCD2 at the protein (A) and gene (B) levels in pan-cancer. Correlation between PDCD2 expression and the expression of PDCD2L, NFKBIB, PRS2, and NFKB1 in GBMLGG (C) . (D, E) Expression and prognosis of PDCD2L, NFKBIB, PRS2, and NFKB1 in GBMLGG.

Article Snippet: The technique of immunohistochemistry (IHC) was carried out following the methods described earlier., The xenograft sections of nude mice were treated with primary antibodies against PDCD2 (Proteintech, 10725-1-AP) and Ki67 (sc-23900, Santa Cruz) for overnight incubation at 4 °C.

Techniques: Expressing

Journal: Genes & Diseases

Article Title: PDCD2 as a prognostic biomarker in glioma correlates with malignant phenotype

doi: 10.1016/j.gendis.2023.101106

Figure Lengend Snippet: KEGG and GO enrichment analysis for PDCD2. The top 50 genes positively (A) and negatively (B) correlated with PDCD2 are shown in the heat map. (C, D) KEGG pathway (C) and biology process analysis (D) of PDCD2.

Article Snippet: The technique of immunohistochemistry (IHC) was carried out following the methods described earlier., The xenograft sections of nude mice were treated with primary antibodies against PDCD2 (Proteintech, 10725-1-AP) and Ki67 (sc-23900, Santa Cruz) for overnight incubation at 4 °C.

Techniques:

Journal: Genes & Diseases

Article Title: PDCD2 as a prognostic biomarker in glioma correlates with malignant phenotype

doi: 10.1016/j.gendis.2023.101106

Figure Lengend Snippet: GSEA enrichment PDCD2-related signaling pathway in GBMLGG.

Article Snippet: The technique of immunohistochemistry (IHC) was carried out following the methods described earlier., The xenograft sections of nude mice were treated with primary antibodies against PDCD2 (Proteintech, 10725-1-AP) and Ki67 (sc-23900, Santa Cruz) for overnight incubation at 4 °C.

Techniques:

Journal: Genes & Diseases

Article Title: PDCD2 as a prognostic biomarker in glioma correlates with malignant phenotype

doi: 10.1016/j.gendis.2023.101106

Figure Lengend Snippet: KEGG enrichment PDCD2-related signaling pathway in GBMLGG.

Article Snippet: The technique of immunohistochemistry (IHC) was carried out following the methods described earlier., The xenograft sections of nude mice were treated with primary antibodies against PDCD2 (Proteintech, 10725-1-AP) and Ki67 (sc-23900, Santa Cruz) for overnight incubation at 4 °C.

Techniques:

Journal: Genes & Diseases

Article Title: PDCD2 as a prognostic biomarker in glioma correlates with malignant phenotype

doi: 10.1016/j.gendis.2023.101106

Figure Lengend Snippet: PDCD2 promotes GBMLGG progression. (A, B) To determine the levels of PDCD2 expression in U251 and U87 cells transfected with siRNA targeting PDCD2, qPCR and Western blotting were employed. (C) Cell growth ability was assessed using CCK8 assays at the specified time intervals in U251 and U87 cells transfected with PDCD2 siRNAs. (D) PDCD2 knockdown inhibited colony formation of both U251 and U87 cells. (E, F) The migration and invasion of U251 and U87 cells were found to be inhibited by PDCD2 knockdown, as demonstrated by the transwell migration and invasion assays (scale bars = 200 μm). U87 cells were injected subcutaneously into nude mice to establish a xenograft model. Following the development of the tumor, intertumoral injection of si-PDCD2 or NC was performed ( n = 3/group). (G – I) Representative pictures and tumor growth chart at 16 days post-injection of si-PDCD2 or NC in GBMLGG xenograft model. (J) The weight of the xenograft tumor was measured and graphed 16 days after the injection. (K) IHC staining was used to examine the alterations in the levels of PDCD2 and Ki-67 in xenograft tumors. Representative images are shown (scale bars = 20 μm). The data were presented as mean ± standard deviation of three independent experiments. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001.

Article Snippet: The technique of immunohistochemistry (IHC) was carried out following the methods described earlier., The xenograft sections of nude mice were treated with primary antibodies against PDCD2 (Proteintech, 10725-1-AP) and Ki67 (sc-23900, Santa Cruz) for overnight incubation at 4 °C.

Techniques: Expressing, Transfection, Western Blot, Knockdown, Migration, Injection, Immunohistochemistry, Standard Deviation